53 related articles for article (PubMed ID: 32361033)
1. Integrated CT imaging and tissue immune features disclose a radio-immune signature with high prognostic impact on surgically resected NSCLC.
Mazzaschi G; Milanese G; Pagano P; Madeddu D; Gnetti L; Trentini F; Falco A; Frati C; Lorusso B; Lagrasta C; Minari R; Ampollini L; Silva M; Sverzellati N; Quaini F; Roti G; Tiseo M
Lung Cancer; 2020 Jun; 144():30-39. PubMed ID: 32361033
[TBL] [Abstract][Full Text] [Related]
2. Preoperative CT-based radiomic prognostic index to predict the benefit of postoperative radiotherapy in patients with non-small cell lung cancer: a multicenter study.
Ma Z; Men Y; Liu Y; Bao Y; Liu Q; Yang X; Wang J; Deng L; Zhai Y; Bi N; Wang L; Hui Z
Cancer Imaging; 2024 May; 24(1):61. PubMed ID: 38741207
[TBL] [Abstract][Full Text] [Related]
3. Novel Radiomic Measurements of Tumor-Associated Vasculature Morphology on Clinical Imaging as a Biomarker of Treatment Response in Multiple Cancers.
Braman N; Prasanna P; Bera K; Alilou M; Khorrami M; Leo P; Etesami M; Vulchi M; Turk P; Gupta A; Jain P; Fu P; Pennell N; Velcheti V; Abraham J; Plecha D; Madabhushi A
Clin Cancer Res; 2022 Oct; 28(20):4410-4424. PubMed ID: 35727603
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of immune cells in the tumor microenvironment of early-stage lung cancer: a meta-analysis.
Tuminello S; Veluswamy R; Lieberman-Cribbin W; Gnjatic S; Petralia F; Wang P; Flores R; Taioli E
Oncotarget; 2019 Dec; 10(67):7142-7155. PubMed ID: 31903172
[TBL] [Abstract][Full Text] [Related]
5. Associations between radiologist-defined semantic and automatically computed radiomic features in non-small cell lung cancer.
Yip SSF; Liu Y; Parmar C; Li Q; Liu S; Qu F; Ye Z; Gillies RJ; Aerts HJWL
Sci Rep; 2017 Jun; 7(1):3519. PubMed ID: 28615677
[TBL] [Abstract][Full Text] [Related]
6. The tumor immune microenvironment in octogenarians with stage I non-small cell lung cancer.
Lee MC; Buitrago DH; Kadota K; Ujiie H; Woo K; Sima CS; Travis WD; Jones DR; Adusumilli PS
Oncoimmunology; 2014 Nov; 3(11):e967142. PubMed ID: 25941595
[TBL] [Abstract][Full Text] [Related]
7. Dataset on the identification of a prognostic radio-immune signature in surgically resected Non Small Cell Lung Cancer.
Mazzaschi G; Milanese G; Pagano P; Madeddu D; Gnetti L; Trentini F; Falco A; Frati C; Lorusso B; Lagrasta C; Minari R; Ampollini L; Silva M; Sverzellati N; Quaini F; Roti G; Tiseo M
Data Brief; 2020 Aug; 31():105781. PubMed ID: 32548224
[TBL] [Abstract][Full Text] [Related]
8. Radiogenomics for predicting p53 status, PD-L1 expression, and prognosis with machine learning in pancreatic cancer.
Iwatate Y; Hoshino I; Yokota H; Ishige F; Itami M; Mori Y; Chiba S; Arimitsu H; Yanagibashi H; Nagase H; Takayama W
Br J Cancer; 2020 Oct; 123(8):1253-1261. PubMed ID: 32690867
[TBL] [Abstract][Full Text] [Related]
9. Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker.
He B; Dong D; She Y; Zhou C; Fang M; Zhu Y; Zhang H; Huang Z; Jiang T; Tian J; Chen C
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32636239
[TBL] [Abstract][Full Text] [Related]
10. Non-invasive decision support for NSCLC treatment using PET/CT radiomics.
Mu W; Jiang L; Zhang J; Shi Y; Gray JE; Tunali I; Gao C; Sun Y; Tian J; Zhao X; Sun X; Gillies RJ; Schabath MB
Nat Commun; 2020 Oct; 11(1):5228. PubMed ID: 33067442
[TBL] [Abstract][Full Text] [Related]
11. Validation of a radiomic approach to decipher NSCLC immune microenvironment in surgically resected patients.
Trentini F; Mazzaschi G; Milanese G; Pavone C; Madeddu D; Gnetti L; Frati C; Lorusso B; Lagrasta CAM; Minari R; Ampollini L; Ledda RE; Silva M; Sverzellati N; Quaini F; Roti G; Tiseo M
Tumori; 2022 Feb; 108(1):86-92. PubMed ID: 33730957
[TBL] [Abstract][Full Text] [Related]
12. Machine learning: an approach to preoperatively predict PD-1/PD-L1 expression and outcome in intrahepatic cholangiocarcinoma using MRI biomarkers.
Zhang J; Wu Z; Zhang X; Liu S; Zhao J; Yuan F; Shi Y; Song B
ESMO Open; 2020 Nov; 5(6):e000910. PubMed ID: 33239315
[TBL] [Abstract][Full Text] [Related]
13. Imaging Biomarkers to Predict and Evaluate the Effectiveness of Immunotherapy in Advanced Non-Small-Cell Lung Cancer.
Liu Y; Wu M; Zhang Y; Luo Y; He S; Wang Y; Chen F; Liu Y; Yang Q; Li Y; Wei H; Zhang H; Jin C; Lu N; Li W; Wang S; Guo Y; Ye Z
Front Oncol; 2021; 11():657615. PubMed ID: 33816314
[TBL] [Abstract][Full Text] [Related]
14. A multi-omics-based serial deep learning approach to predict clinical outcomes of single-agent anti-PD-1/PD-L1 immunotherapy in advanced stage non-small-cell lung cancer.
Yang Y; Yang J; Shen L; Chen J; Xia L; Ni B; Ge L; Wang Y; Lu S
Am J Transl Res; 2021; 13(2):743-756. PubMed ID: 33594323
[TBL] [Abstract][Full Text] [Related]
15. Pretreatment CT-Based Radiomics Signature as a Potential Imaging Biomarker for Predicting the Expression of PD-L1 and CD8+TILs in ESCC.
Wen Q; Yang Z; Zhu J; Qiu Q; Dai H; Feng A; Xing L
Onco Targets Ther; 2020; 13():12003-12013. PubMed ID: 33244242
[TBL] [Abstract][Full Text] [Related]
16. Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade.
Vaidya P; Bera K; Patil PD; Gupta A; Jain P; Alilou M; Khorrami M; Velcheti V; Madabhushi A
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33051342
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemistry and Radiomic Features for Survival Prediction in Small Cell Lung Cancer.
Gkika E; Benndorf M; Oerther B; Mohammad F; Beitinger S; Adebahr S; Carles M; Schimek-Jasch T; Zamboglou C; Frye BC; Bamberg F; Waller CF; Werner M; Grosu AL; Nestle U; Kayser G
Front Oncol; 2020; 10():1161. PubMed ID: 32903606
[No Abstract] [Full Text] [Related]
18. [Advances in Pseudoprogression of Immune Checkpoint Inhibitors
in Non-small Cell Lung Cancer].
Tong Y; Long Y; Zhang F; Li J
Zhongguo Fei Ai Za Zhi; 2024 Apr; 27(4):306-320. PubMed ID: 38769834
[TBL] [Abstract][Full Text] [Related]
19. Radiomics model based on intratumoral and peritumoral features for predicting major pathological response in non-small cell lung cancer receiving neoadjuvant immunochemotherapy.
Huang D; Lin C; Jiang Y; Xin E; Xu F; Gan Y; Xu R; Wang F; Zhang H; Lou K; Shi L; Hu H
Front Oncol; 2024; 14():1348678. PubMed ID: 38585004
[TBL] [Abstract][Full Text] [Related]
20. A whirl of radiomics-based biomarkers in cancer immunotherapy, why is large scale validation still lacking?
Ligero M; Gielen B; Navarro V; Cresta Morgado P; Prior O; Dienstmann R; Nuciforo P; Trebeschi S; Beets-Tan R; Sala E; Garralda E; Perez-Lopez R
NPJ Precis Oncol; 2024 Feb; 8(1):42. PubMed ID: 38383736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
